Singapore markets closed

ENDRA Life Sciences Inc. (NDRA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.0971-0.0059 (-5.73%)
At close: 04:00PM EDT
0.0975 +0.00 (+0.41%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.1030
Open0.1010
Bid0.0966 x 3600
Ask0.0986 x 2800
Day's range0.0940 - 0.1032
52-week range0.0690 - 2.7900
Volume7,559,418
Avg. volume18,588,684
Market cap6.824M
Beta (5Y monthly)1.06
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

    ANN ARBOR, Mich., June 04, 2024--ENDRA Life Sciences Inc. (Nasdaq: NDRA) ("ENDRA" or the "Company"), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold.

  • Business Wire

    ENDRA Provides Update Following In-person Meeting with FDA

    ANN ARBOR, Mich., May 20, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced that it has completed what it considers to be a highly informative pre-submission meeting with the U.S. Food and Drug Administration (FDA) related to the clinical trial design of the TAEUS liver device in support of its U.S. De Novo filing.

  • Business Wire

    ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update

    ANN ARBOR, Mich., May 14, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2024 and provided a business update.